08:56 AM EDT, 10/20/2025 (MT Newswires) -- Rapt Therapeutics ( RAPT ) and Shanghai Jeyou Pharmaceutical said Monday that their jointly developed therapy RPT904 dosed at eight-week or 12-week intervals in a mid-stage trial was about as effective and safe as omalizumab dosed every four weeks.

The companies said RPT904 was well tolerated with no serious adverse results related to study drug and no treatment-related adverse events resulting in treatment discontinuation.

The companies said the results of the 137-patient trial merit advancing RPT904 to late-stage development in China, with next steps to be discussed with the US Food and Drug Administration and other regulatory authorities.

Chronic spontaneous urticaria is an autoimmune disorder characterized by the sudden onset of debilitating hives and intense itch.

Shares of Rapt were up more than 52% in recent Monday premarket activity.